SCHEMBL5547686

SCHEMBL5547686

[CH2]c1cccc(-c2csnn2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.56
KMT2A Q03164 5/20 0.56
NPC1 O15118 3/20 0.56
MEN1 O00255 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
ALDH1A1 P00352 1/20 0.54
CYP1A2 P05177 1/20 0.54
CYP2C9 P11712 1/20 0.54
HPGD P15428 1/20 0.54
CYP2C19 P33261 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
POLB P06746 3/20 0.47
NOTUM Q6P988 1/20 0.47
GAA P10253 3/20 0.42
MAPK1 P28482 1/20 0.42
LMNA P02545 2/20 0.41
MGLL Q99685 1/20 0.40
MAPT P10636 4/20 0.38
PKM P14618 2/20 0.38
CDC25A P30304 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8346377 0.78 KMT2A (0.61) RAB9AKMT2ANPC1MEN1SMN1; SMN2
SCHEMBL16636188 0.78 KMT2A (0.56) RAB9AKMT2ANPC1MEN1SMN1; SMN2
SCHEMBL4750607 0.78 KMT2A (0.56) RAB9AKMT2ANPC1MEN1SMN1; SMN2
SCHEMBL29683694 0.78 KMT2A (0.56) RAB9AKMT2ANPC1MEN1SMN1; SMN2
SCHEMBL28571840 0.78 KMT2A (0.56) RAB9AKMT2ANPC1MEN1SMN1; SMN2
SCHEMBL28615179 0.78 RAB9A (0.56) RAB9AKMT2ANPC1MEN1SMN1; SMN2
SCHEMBL1260494 0.76 KMT2A (0.64) RAB9AKMT2ANPC1MEN1SMN1; SMN2
SCHEMBL69349 0.76 KMT2A (0.91) RAB9AKMT2ANPC1MEN1SMN1; SMN2
SCHEMBL11382735 0.74 RAB9A (0.72) RAB9AKMT2ANPC1MEN1SMN1; SMN2
SCHEMBL28763345 0.73 NPC1 (0.50) RAB9AKMT2ANPC1MEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
CN-101255170-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-09-03 CN disclosed
CN-101172981-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-05-07 CN disclosed
CN-100366624-C 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds OTSUKA PHARMA CO LTD (JP) 2008-02-06 CN disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 RAB9A 2824/4885KMT2A 4267/4885NPC1 2404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.